A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement

Study on Investigational Medication and Chemotherapy in Infants with a Type of Blood Cancer

Recruiting
1 years or below
All
Phase N/A
1 Location

Brief description of study.

This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.

Detailed description of study

The purpose of this study is to evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-R).
Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Lymphoblastic Leukemia (ALL) ,Acute Lymphoblastic Leukemia,ALL,leukemia,pediatric,infant,baby,cancer,oncology
  • Age: 1 years or below
  • Gender: All

Inclusion Criteria
Infants must be > 36 weeks gestational age at the time of enrollment
Patients must have newly diagnosed B lymphoblastic leukemia(also termed B-precursor acute lymphoblastic leukemia) or acute leukemia of ambiguous lineage (ALUL), which includes mixed phenotype acute leukemia (MPAL)
Exclusion Criteria
Patients with known absence of KMT2A-rearrangement leukemia prior to enrollment
Patients with Down syndrome
Patients with secondary B acute lymphoblastic leukemia (B-ALL) that developed after treatment of a prior malignancy with cytotoxic chemotherapy
With the exception of steroid pretreatment or the administration of intrathecal methotrexate per protocol dosing, receipt of any other prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL15P1

Updated on 19 Feb 2024. Study ID: 1704973993 (PHO-FALLON-COG-AALL15P1)

This study investigates the effects of an investigational medication combined with chemotherapy in infants who have a specific type of leukemia called acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement. The purpose of the study is to see if the investigational medication can be safely added to the standard chemotherapy treatment for these young patients.

Participants in this study will receive the investigational medication along with the standard chemotherapy regimen known as Interfant-06. This study aims to evaluate how well infants tolerate this combination treatment. The investigational medication is being tested to see if it can be safely used with the existing treatment plan.

  • Who can participate: Infants must be over 36 weeks gestational age and have a recent diagnosis of B lymphoblastic leukemia or acute leukemia of ambiguous lineage, excluding those with Down syndrome or a history of secondary leukemia after prior chemotherapy.
  • Study details: Participants will receive a combination of the investigational medication and standard chemotherapy. A placebo is not used in this study.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here